Microtubule associated protein, Tau characterizes a number of neurodegenerative disorders grouped as Tauopathies including Alzheimer’s disease (AD) and tau associated frontotemporal lobar degeneration (FTLD-tau). The molecular pathogenesis of these tauopathies involves post-translational modifications of Tau such as phosphorylation and truncation. However, there are other PTMs such as acetylation, methylation, ubiquitination which contribute to the pathogenesis as well. In recent years, a remarkable number of investigations have been efforted on Tau in relation to AD or FLTD-tau which has provided a body of new insights on the possible mechanisms on tau pathology. These involve but not limited to the contexts of tau phosphorylation, Tau-RNA Interaction, MAPT translation suppression, new non-aggregative tau identification, Aβ mediated exosomal tau seed, Clusterin enhanced tau aggregation, co-factor-free tau seed, co-occurrence of tau accumulation and microglial activation, tau acetylation mediated CMA inhibition, Viral ligand-receptor interactions mediated seed transmission, autophagy etc. Early detection is considered as preliminary step in disease management. Recent studies demonstrated positron emission tomography (PET) as an efficient scanner of abnormal tau which has revealed new possibilities of predicting memory impairment, level of toxic tau, detecting previously undetected diffuse pathology and identification of tau generation and deposition. Reports also suggest new advancement on understanding of physiological management of tau pathologies by autophagy mediated tau degradation, inhibition of amyloid formation and tau accumulation. This review summarizes the recent evidences on the nature and action of tau protein with regard to AD and other tauopathies to accumulate new insights into possible mechanisms underlying, detection and diagnosis, biological management and therapeutic strategies.